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Abstract
Objective: History, clinical examination
and throat culture may be inadequate to
rule in or out the presence of group A
streptococci (GAS) infection in patients
with sore throat in a remote location.
We correlated the diagnostic accuracy
for guiding antibiotic prescription of
clinical decision and physiological scor-
ing systems to a rapid diagnostic point
of care (POC) test result in paediatric
patients presenting with sore throat.
Methods: Prospective diagnostic acc-
uracy study conducted between 30
June 2014 and 27 February 2015 in a
remote Australian ED using a
convenience sample. Among paediatric
patients presenting with sore throat,
the Centor criteria and clinical decision
were documented. Simultaneously,
patients without sore throat or
respiratory tract infection were tested
to determine the number of carriers. A
throat swab on all patients was tested
using a POC test (Alere TestPack +Plus
Strep A with on board control),
considered as reference standard to
detect GAS infection.
Results: A total of 101 patients with
sore throat were tested with 26
(25.7%) positive for GAS. One
hundred and forty-seven patients with-
out sore throatwere testedwith one pos-
itive POC test result (specificity 99%;
95% CI 96–100). Positive predictive
value for clinician decision-making for
a positiveGAS swab (bacterial infection)
was 29% (95% CI 17–43), negative
predictive value 78% (95% CI 63–88).
Area under ROC for the Centor score
was 0.70 (95% CI 0.58–0.81).
Conclusion: Clinician judgement and
Centor score are inadequate tools for
clinical decision-making for children
presenting with sore throat. Adjunc-
tive POC testing provides sufficient ac-
curacy to guide antibiotic prescription
on first presentation.
Key words: accuracy of antibiotic
prescribing, Centor score, clinical
reasoning, group A streptococci,
pharyngitis, point of care testing.
Introduction
Invasive group A streptococci (GAS)
infections include a wide range of
conditions with different clinical
presentations; patients may present in
clusters and show different manifesta-
tions.1 The global burden of GAS
disease predominantly relates to two
complications: acute rheumatic fever
(ARF) and chronic rheumatic heart
disease (CRHD). Estimates range
from approximately 24000002 to
120000003 cases of CRHD world-
wide. Observations in the Northern
Territory, Australia, showed an
annual incidence of approximately
0.4% for ARF and 2% for CRHD,
32% of these in the age group of
35–44years.4 The Indigenous popula-
tion of the adjacent northwest of
Queensland represents one of the
highest incidences of ARF and related
complications in the world with an
annual incidence of up to 492/100000
in children aged 4–15years,5 correlating
with a high proportion of residents liv-
ing in remote communities and with
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Key findings
• Clinician judgement and Centor
score are inadequate tools for
decision-making.
• A POC test provides sufficient
accuracy to guide antibiotic pre-
scription.
• One out of four patients present-
ing with sore throat had a GAS
infection.
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low socioeconomic standard. It is con-
sistent with findings from the Northern
Territory.6 There is little evidence on
the costs related to this disease burden.
World Health Organisation (WHO)
statements suggest that ARF and
CRHD cause an additional socioeco-
nomic burden especially in low-income
countries.7 ARF and CRHD costs in
the USA in 2002 were estimated to be
approximately US$1.9 billion,8 and in
New Zealand, annual costs for admis-
sions due to ARF and CRHD are as
high as the hospitalisation costs
for pneumococcal disease and
Haemophilus influenzae-related otitis
media combined.9
The prevalence of GAS among
patients presenting with a sore throat
ranges from close to 0% to 40%.10–12
While there is increasing suspicion
and some evidence that ARF may also
be related to chronic skin sores
(pyoderma),4,13 the Australian guide-
lines4 focus primarily on respiratory
tract infections as a cause of ARF
and suggest primary prevention by
‘…treating GAS infection effectively
to prevent the development of ARF
in individuals’, also recommending
secondary prevention with monthly
benzylpenicillin injections.4 This has
been expensive and not always effec-
tive, even if patients were compliant.14
Treating every patient presenting
with a sore throat with antibiotics
has been suggested for Indigenous
communities in central and northern
Australia, Maori and Pacific Islander
people,15 but prescribing antibiotics
for every sore throat is discouraged,
citing risks of emerging antibiotic
resistance.4,7
While there are a large number of
studies worldwide and several studies
in the Northern Territories about the
epidemiology of GAS pharyngitis, no
study has been published that focuses
on primary prevention and the treat-
ment decision for patients with pharyn-
gitis in remote northwestQueensland, a
region with a high number of Aborigi-
nal patients at risk for ARF and
CRHD.4,5
Clinical decision aides (Centor,
Breese, McIssaac, Wald and Attia
scores,16 WHO scoring system) have
been suggested to rule in or out
patients for antibiotic treatment of
suspected GAS pharyngitis but have
not proven to be reliable enough to
guide antibiotic prescription.3,11,16,17
Throat culture has been recommended
for treatment decisions.11 In an ED in a
remote community, it is difficult to
organise re-presentation or follow up
of results including treatment modifi-
cations because many patients are
travelling up to several hundreds of
kilometres on gravel roads to be seen
in the ED.
Among the patients presenting with
a sore throat, we aimed to compare
the performance of the Centor criteria
and actual clinical decision-making to
evaluate their correlation with the
presence of group A streptococci.
Objective
The study compares the accuracy of
methods for decision-making to guide
antibiotic prescription on patients pre-
senting to a base hospital ED in the
most remote location in Queensland
with a sore throat. Clinical decision
for antibiotic prescription and Centor
criteria were compared with a cheap
and easy to use GAS antigen test kit.
Methods
Setting
The Mount Isa Hospital ED serves
50000–60000 residents, travellers
and fly-in–fly-out workers in an area
of 308800km2. It is a Queensland
Health Clinical Services Capability
Framework Level 4 Department (Base
Hospital Specialist Service) seeing
29500–40000 annual presentations.
Of the presentations, 20–25% are
paediatric patients; 40% are Indige-
nous patients.
Design
A single centre prospective diagnostic
accuracy study was conducted at the
Mount Isa Hospital ED in Queens-
land, Australia, using a convenience
sample of patients presenting between
30 June 2014 and 27 February 2015
with and without sore throat. Data
were prospectively collected, the
treating clinician blinded for the swab
results.
Participants
Children aged 3–15years presenting
with a sore throat were enrolled.
Exclusion criteria were representation
for a sore throat and already taking
antibiotics. Simultaneously, children
with no sore throat, presenting for
other reasons than a respiratory tract
infection and not taking antibiotics,
were enrolled as a control group.
Measurements/Protocol
Symptoms and signs were prospec-
tively registered on a standardised
score sheet for each participant. For
patients presenting with a sore throat,
the clinician’s impression of the cause
(bacterial/viral/unsure), the treatment
(whether antibiotics prescribed or
not) and the four Centor criteria – ton-
sillar exudates, swollen tender anterior
cervical node, lack of a cough and his-
tory of fever17 – were documented. In
the Mount Isa Hospital ED, every pa-
tient is reviewed by a Senior Medical
Officer (FACEM, FACRRM or
FRACGP); thus, the study reflects the
senior clinician’s impression.
Presence of GAS was investigated
using the Alere™ TestPack +Plus Strep
A (Alere, Waltham, MA, USA) with
on board control (OBC). The accuracy
of several rapid antigen tests has been
deemed sufficient for diagnosis and
management of GAS infections,18,19
including the Alere™ TestPack +Plus
StrepAwithOBC that has been proven
to perform with enough accuracy20,21
to be comparable with a throat cul-
ture.12 It was therefore used as the ref-
erence standard for this evaluation.
After obtaining the carer’s informed
consent, a throat swab was obtained
with a Dacron swab (Alere). This swab
was stored at 6°C until the test was
performed. The study team processed
the swabs within 72h. Clinicians were
blinded to the result of the swab.
Statistical analysis
Continuous variables were summarised
using mean (standard deviation), while
discrete variables were summarised
using counts (proportion). The Stu-
dent’s t-test was used to calculate signif-
icance of difference between means,
and the χ2 test was used to calculate
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significance of difference between pro-
portions, except where value in a cell
was less than 5, when the Fisher’s exact
test was used. Using the POC test re-
sults as the reference standard, clinical
decision-making and Centor criteria
were evaluated for specificity, sensitiv-
ity, predictive values and likelihood
ratios to detect GAS infection and
reported with 95% confidence intervals
(CIs). The clinicians’ impression (GAS
infection or viral infection) and pre-
scription of antibiotics were docu-
mented. Predictive accuracy of
accumulative effect of these variables
within the Centor score was assessed
by measuring the area under a receiver
operating characteristic (ROC) curve.
All analyses were conducted using
STATA v 11.0 (StataCorp, College
Station, TX, USA). A P-value of
<0.05 was considered to be statistically
significant.
For the purpose of sample size calcu-
lation, we assumed a true positive rate
of samples tested using the POC to be
99% and a minimum clinically impor-
tant true positive rate of clinical
decision-making to be 90%. Using
95% CI (two-sided alpha of 0.05)
and power of 80%, the sample size
estimated was 100 patients presenting
with a sore throat.
The study was approved by the
Townsville Hospital and Health Ser-
vice Human Research and Ethics
Committee (HREC/13/QTHS/260).
Results
There were 250 children aged
3–15years screened, and 248 throat
swabs collected. Two parents refused
the collection of swabs. Among these
147 children presented without a sore
throat (79 [54%] male, mean age of
8.3 (3.5) years, 71 (48%) Indigenous).
Out of these, one POC test result was
positive. Hence, the specificity of the
POC to rule out true infection caused
by GAS can be estimated to 99%
(95% CI 96–100).
There were 101 patients included
that presented with a sore throat (43
[43%] were male, mean age 7.9years,
49 [49%] Indigenous; 52 were
prescribed antibiotics). There were no
differences in demographics between
patients prescribed antibiotics and
those that were not. Antibiotic
prescription was more common in the
presence of tonsillar exudate and
tender anterior cervical lymph nodes
(Table 1). Twenty-six (26%) patients
tested positive for GAS; 11 of these
were not prescribed antibiotics. Except
for one of these cases, this was consis-
tent with the clinician’s impression that
the pharyngitis/sore throat was not of
bacterial origin.
The positive predictive value for cli-
nician decision-making for a positive
GAS swab (bacterial infection) was
29% (95% CI 17–43), with a negative
predictive value of 78% (95% CI 63–
88). Specificity of clinical decision-
making was 51% (95% CI 39–62),
sensitivity was 58% (95% CI 37–77),
a positive likelihood ratio of 1.17
(95% CI 0.78–1.75) and a negative
likelihood ratio of 0.83 (95% CI
0.51–1.38). Performance of the Centor
score to detect GAS infection showed
an area under ROC of 0.70 (95% CI
0.58–0.81) (Fig. 1).
Sensitivity, specificity, positive and
negative likelihood ratios of different
cut-point values for the Centor score
are shown in Table 2. The association
between Centor score and the number
of patients with GAS positive is listed
in Table 3. The positive predictive value
for a Centor score of 1 point or more
and positive GAS swab was 50%
(95% CI 31–69), with a negative pre-
dictive value of 84% (95% CI 70–91).
Discussion
Patients presenting to the Mount Isa
Hospital EDwith a sore throat showed
a high prevalence of GAS infection
(26%), resulting in a high positive
predictive value of the POC test. While
there have been high GAS prevalence
found in the USA (20–30%)12 and





prescribed (n= 52) P
Age (years) 7.6 (3.2) 8.5 (4.3) 0.22
Male sex 20 (41%) 23 (44%) 0.73
Race 0.95
Caucasian 23 (47%) 23 (44%)
Indigenous 23 (47%) 26 (50%)
Other 3 (6.2%) 3 (5.8%)
Tonsillar exudate 2 (4.1%) 15 (29%) <0.01
Tender anterior cervical
lymph nodes
12 (25%) 24 (46%) 0.02
Absence of cough 8 (16%) 13 (25%) 0.28
Fever 17 (35%) 21 (40%) 0.55
Clinical diagnosis < 0.01
Uncertain 1 (2.0%) 7 (14%)
Strep throat 1 (2.0%) 22 (42%)
Other bacterial 0 4 (7.7%)
Viral 47 (96%) 19 (37%)
Centor criteria score 0.05
0 22 (45%) 12 (23%)
1 18 (37%) 21 (40%)
2 7 (14%) 8 (15%)
3 1 (2.0%) 8 (15%)
4 1 (2.0%) 3 (5.8%)
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Europe (30–40%),22 studies in the
northern parts of the Northern Terri-
tory show a very low prevalence of
GAS infection (0.1%).10 This alerts to
the fact that the prevalence docu-
mented in studies in other areas of
Australia may not apply to northwest
Queensland.10
The positive predictive value of the
clinicians’ decision to prescribe antibi-
otics was low, with prescription of
antibiotics being appropriate in less
than one out of three patients. Impor-
tantly, in about one out of three pa-
tients, no antibiotics were prescribed
despite of the presence of a GAS phar-
yngitis (positive GAS POC test). The
Centor criteria showed a similar result
in detecting GAS infections. This find-
ing is consistent with the results of the
study defining the Centor variables in
1981;17 the area under ROC is also
comparable with the one reported for
the Attia score.23
The incidence of GAS colonisation
of the pharynx of asymptomatic
patients in literature is controversial
and ranges from less than 2% to 11%
per year.13,24 The positive rate of
GAS swabs in the control group was
low (<1%) much lower than found in
the Northern Territory (3.7%).10
Therefore, it is unlikely that they have
confounded the results, implying that
the test has some value for ruling in
patients with positive GAS swab for
antibiotic treatment in a setting similar
to Mount Isa with high prevalence of
GAS pharyngitis and low prevalence
of asymptomatic carriers. However,
in settings with lower prevalence and
higher carrier rates, the positive
predictive value of the POC test will
be too low to rule in patients for antibi-
otic treatment.
Clinical identification of GAS throat
infection may be challenging,25 and a
high number of patients may be
treated inadequately, including both
unnecessary antibiotic prescriptions
and patients belonging to high-risk
groups left untreated. Clinical decision
rules have not shown appropriate pre-
dictive values to be deemed sufficient
for clinical decision-making alone
whether or not to treat a sore throat
as a GAS infection.3,12,26
Prescribing antibiotics to every patient
presenting with a sore throat is not rec-
ommended because of potential side ef-
fects and the risks of increasing
antibiotic resistance.4,7,27 Focussing on
patients with severe pharyngitis alone
may increase the positive predictive
value of a decision-making rule, but
would focus only on a small subgroup
of patients,27 leaving a large proportion
inadequately treated and at risk of future
complications. Use of an appropriate
POC test appears to improve the
number of appropriately treated patients
presentingwith a sore throat, not only in
avoiding unnecessary antibiotic
Figure 1. Receiver operating characteristic curve (1 – specificity) for Centor score to
predict group A streptococci positive swab. The four Centor criteria are: tonsillar exudates,
tender swollen anterior cervical nodes, lack of a cough and history of a fever (one point for
each positive criterion).
TABLE 2. Performance of the Centor score at different cut-points









≥0 100 (95–100) 0.0 (0–13) 74 (65–82) — 1.0 (1.0–1.0) —
≥1 85 (65–96) 40 (29–52) 88 (73–97) 33 (22–45) 1.4 (1.1–1.8) 0.39 (0.15–0.99)
≥2 54 (33–73) 81 (71–89) 50 (31–69) 84 (73–91) 2.9 (1.6–5.2) 0.57 (0.37–0.87)
≥3 23 (9.0–44) 91 (82–96) 46 (19–75) 77 (67–86) 2.5 (0.9–6.7) 0.85 (0.68–1.1)
=4 3.9 96 25 (0.63–81) 74 (64–83) 0.96 (0.10–8.8) 1.00 (0.92–1.1)








0 30 4 34
1 31 8 39
2 7 8 15
3 4 5 9
4 3 1 4
U ORDA ETAL.202
© 2016 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College for
Emergency Medicine and Australasian Society for Emergency Medicine
treatment but also in appropriately
treating thosewith a positiveGAS result.
Utilising a GAS POC test is expected
to reduce long-term costs by lowering
the disease burden of complications of
streptococcal infections, especially ARF
and CRHD. Antibiotic treatment with
penicillin will cost approximately AUD
$10 for every unnecessary penicillin pre-
scription (not including costs for poten-
tial side effects). Performing aGASPOC
test will cost approximately AUD$4 per
test and will be outweighed by the cost
savings due to avoiding unnecessary an-
tibiotic prescriptions in regions of low
prevalence of GAS pharyngitis.
Culture has been deemed the gold
standard, not only for diagnostics in
clinical practice but also for rating
other diagnostic methods.11,18 How-
ever, a throat culture is much more ex-
pensive than a POC test, and
sensitivity of throat cultures is not
higher than sensitivity of modern
POC tests. Polymerase chain reaction
(PCR) testing has shown positive re-
sults on patient samples testing posi-
tive with a rapid antigen test but
negative with culture, demonstrating
that sensitivity of culture is not
100%.28 The later generations of rapid
antigen detection tests are cheap, easy
to use and have been more sensitive
than culture when assessed against
PCR as the standard,28,29 also demon-
strating negative predictive values
around 99%.30 Therefore, a POC
rapid antigen test is an ideal tool to
support decision-making – not only in
EDs but also in other primary care
settings.
Limitations
It is a single centre design study using a
small convenience sample. However,
this small study demonstrates that
testing and treatment decisions need
to be tailored to the region. A larger,
ongoing collection of samples from pa-
tients in the region presentingwith sore
throat is recommended, including fol-
lowing up those with sore throat and
positive initial test to gain more infor-
mation about chronic GAS colonisa-
tion and asymptomatic GAS carriers;
however, it would need appropriate
funding.
Longer-term follow up was not
available and would have been useful
to define the clinical relevance and
outcome of treatment linked to the test
results, especially in regards to
avoiding representations and compli-
cations. The value of a POC test in
comparison with clinician decision-
making or clinical decision rules may
differ between populations.
Conclusion
Clinical decision-making and utilisation
of clinical decision rules are inadequate
to guide treatment of children present-
ing with sore throat.
The use of a POC test is indicated to
improve the accuracy of antibiotic pre-
scribing for children presenting with
sore throat in the setting of a remote ED.
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